In the ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), patients with coexisting medical conditions have been noted to be at a higher risk of progressive and severe disease. Patients with multiple sclerosis (MS), who are often on immunosuppressive therapy, may be among these high-risk groups.
A new study, released on the medRxiv* preprint server, examines the associations between immunosuppressive disease-modifying therapies (DMTs) used in MS with adverse outcomes in an international cohort of patients with MS COVID-19.
